Yanbo Fan1, Haocheng Lu1, Yanhong Guo1, Tianqing Zhu1, Minerva T Garcia-Barrio2, Zhisheng Jiang3, Cristen J Willer4, Jifeng Zhang1, Y Eugene Chen5. 1. Cardiovascular Center, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan. 2. Cardiovascular Research Institute, Morehouse School of Medicine, Atlanta, Georgia. 3. Institute of Cardiovascular Disease, Key Laboratory for Arteriosclerology of Hunan Province, University of South China, Hengyang, China. 4. Cardiovascular Center, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan; Department of Human Genetics, University of Michigan, Ann Arbor, Michigan; Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan. 5. Cardiovascular Center, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan. Electronic address: echenum@umich.edu.
Abstract
BACKGROUND & AIMS: The rs58542926 C>T variant of the transmembrane 6 superfamily member 2 gene (TM6SF2), encoding an E167K amino acid substitution, has been correlated with reduced total cholesterol (TC) and cardiovascular disease. However, little is known about the role of TM6SF2 in metabolism. We investigated the long-term effects of altered TM6SF2 levels in cholesterol metabolism. METHODS: C57BL/6 mice (controls), mice that expressed TM6SF2 specifically in the liver, and mice with CRISPR/Cas9-mediated knockout of Tm6sf2 were fed chow or high-fat diets. Blood samples were collected from all mice and plasma levels of TC, low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol, and triglycerides were measured. Liver tissues were collected and analyzed by histology, real-time polymerase chain reaction, and immunoblot assays. Adenovirus vectors were used to express transgenes in cultured Hep3B hepatocytes. RESULTS: Liver-specific expression of TM6SF2 increased plasma levels of TC and LDL-c, compared with controls, and altered liver expression of genes that regulate cholesterol metabolism. Tm6sf2-knockout mice had decreased plasma levels of TC and LDL-c, compared with controls, and consistent changes in expression of genes that regulate cholesterol metabolism. Expression of TM6SF2 promoted cholesterol biosynthesis in hepatocytes. CONCLUSIONS: TM6SF2 regulates cholesterol metabolism in mice and might be a therapeutic target for cardiovascular disease.
BACKGROUND & AIMS: The rs58542926 C>T variant of the transmembrane 6 superfamily member 2 gene (TM6SF2), encoding an E167K amino acid substitution, has been correlated with reduced total cholesterol (TC) and cardiovascular disease. However, little is known about the role of TM6SF2 in metabolism. We investigated the long-term effects of altered TM6SF2 levels in cholesterol metabolism. METHODS: C57BL/6 mice (controls), mice that expressed TM6SF2 specifically in the liver, and mice with CRISPR/Cas9-mediated knockout of Tm6sf2 were fed chow or high-fat diets. Blood samples were collected from all mice and plasma levels of TC, low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol, and triglycerides were measured. Liver tissues were collected and analyzed by histology, real-time polymerase chain reaction, and immunoblot assays. Adenovirus vectors were used to express transgenes in cultured Hep3B hepatocytes. RESULTS: Liver-specific expression of TM6SF2 increased plasma levels of TC and LDL-c, compared with controls, and altered liver expression of genes that regulate cholesterol metabolism. Tm6sf2-knockout mice had decreased plasma levels of TC and LDL-c, compared with controls, and consistent changes in expression of genes that regulate cholesterol metabolism. Expression of TM6SF2 promoted cholesterol biosynthesis in hepatocytes. CONCLUSIONS:TM6SF2 regulates cholesterol metabolism in mice and might be a therapeutic target for cardiovascular disease.
Authors: María Eugenia Miquilena-Colina; Elena Lima-Cabello; Sonia Sánchez-Campos; María Victoria García-Mediavilla; Miguel Fernández-Bermejo; Tamara Lozano-Rodríguez; Javier Vargas-Castrillón; Xabier Buqué; Begoña Ochoa; Patricia Aspichueta; Javier González-Gallego; Carmelo García-Monzón Journal: Gut Date: 2011-01-26 Impact factor: 23.059
Authors: Bratati Kahali; Yang-Lin Liu; Ann K Daly; Christopher P Day; Quentin M Anstee; Elizabeth K Speliotes Journal: Gastroenterology Date: 2015-01-29 Impact factor: 22.682
Authors: Hovsep Mahdessian; Apostolos Taxiarchis; Sergej Popov; Angela Silveira; Anders Franco-Cereceda; Anders Hamsten; Per Eriksson; Ferdinand van't Hooft Journal: Proc Natl Acad Sci U S A Date: 2014-06-04 Impact factor: 11.205
Authors: John Willy Haukeland; Jan Kristian Damås; Zbigniew Konopski; Else Marit Løberg; Terese Haaland; Ingeborg Goverud; Peter A Torjesen; Kåre Birkeland; Kristian Bjøro; Pål Aukrust Journal: J Hepatol Date: 2006-03-20 Impact factor: 25.083
Authors: Martina Goffredo; Sonia Caprio; Ariel E Feldstein; Ebe D'Adamo; Melissa M Shaw; Bridget Pierpont; Mary Savoye; Hongyu Zhao; Allen E Bale; Nicola Santoro Journal: Hepatology Date: 2015-11-16 Impact factor: 17.425
Authors: Daniel Seung Kim; Anne U Jackson; Yatong K Li; Heather M Stringham; Johanna Kuusisto; Antti J Kangas; Pasi Soininen; Mika Ala-Korpela; Charles F Burant; Veikko Salomaa; Michael Boehnke; Markku Laakso; Elizabeth K Speliotes Journal: J Lipid Res Date: 2017-05-24 Impact factor: 5.922
Authors: Nicole Ehrhardt; Michael E Doche; Shuang Chen; Hui Z Mao; Meghan T Walsh; Candy Bedoya; Maha Guindi; Weidong Xiong; Joseph Ignatius Irudayam; Jahangir Iqbal; Sebastien Fuchs; Samuel W French; M Mahmood Hussain; Moshe Arditi; Vaithilingaraja Arumugaswami; Miklós Péterfy Journal: Hum Mol Genet Date: 2017-07-15 Impact factor: 5.121
Authors: Elena V Feofanova; Elise Lim; Han Chen; MinJae Lee; Ching-Ti Liu; L Adrienne Cupples; Eric Boerwinkle Journal: Genet Epidemiol Date: 2021-06-24 Impact factor: 2.344